High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor

Molecular Immunology

Volumn 43, Issue 13, 2006, Pages 2119-2123

  Ferraz, Rosa María ^a   Arís, Anna ^a   Martínez, Miguel Angel ^b   Villaverde, Antonio ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adaptive binding; Allosteric biosensor; Antibody; HIV; IgG4; Immunosensor; Viral infection

Indexed keywords

BETA GALACTOSIDASE; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G4; VIRUS ENVELOPE PROTEIN;

ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSOR; SIGNAL TRANSDUCTION;

ANTIBODIES, VIRAL; BINDING SITES, ANTIBODY; BIOSENSING TECHNIQUES; EPITOPES; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MALE; NANOTECHNOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645844244     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2005.12.012     Document Type: Article

References (30)

1. Aalberse R.C., and Schuurman J. IgG4 breaking the rules. Immunology 105 (2002) 9-19
2. Abbas A., Vasilescu A., Do H., Hendel H., Maachi M., Goutalier F.X., Regulier E.G., Rappaport J., Matsuda F., Therwath A., Aucouturier P., and Zagury JF. Analysis of IGG and IGG4 in HIV-1 seropositive patients and correlation with biological and genetic markers. Biomed. Pharmacother. 59 (2005) 38-46
3. Benito A., Feliu J.X., and Villaverde A. Beta-galactosidase enzymatic activity as a molecular probe to detect specific antibodies. J. Biol. Chem. 271 (1996) 21251-21256
4. Benito A., Mateu M.G., and Villaverde A. Improved mimicry of a foot-and-mouth disease virus antigenic site by a viral peptide displayed on beta-galactosidase surface. Biotechnology (N.Y.) 13 (1995) 801-804
5. Broliden P.A., von Gegerfelt A., Clapham P., Rosen J., Fenyo E.M., Wahren B., and Broliden K. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 461-465
6. Cavacini L.A., Emes C.L., Wisnewski A.V., Power J., Lewis G., Montefiori D., and Posner MR. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses 14 (1998) 1271-1280
7. de Rosny E., Vassell R., Jiang S., Kunert R., and Weiss CD. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J. Virol. 78 (2004) 2627-2631
8. Feliu J.X., Benito A., Oliva B., Aviles F.X., and Villaverde A. Conformational flexibility in a highly mobile protein loop of foot-and-mouth disease virus: distinct structural requirements for integrin and antibody binding. J. Mol. Biol. 283 (1998) 331-338
9. Feliu J.X., Ferrer-Miralles N., Blanco E., Cazorla D., Sobrino F., and Villaverde A. Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. Biochim. Biophys. Acta 1596 (2002) 212-224
10. Feliu J.X., Ramirez E., and Villaverde A. Distinct mechanisms of antibody-mediated enzymatic reactivation in beta-galactosidase molecular sensors. FEBS Lett. 438 (1998) 267-271
11. Feliu J.X., and Villaverde A. Engineering of solvent-exposed loops in Escherichia coli beta-galactosidase. FEBS Lett. 434 (1998) 23-27
12. Ferraz R.M., Aris A., and Villaverde A. Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem. Biophys. Res. Commun. 314 (2004) 854-860
13. Ferrer-Miralles N., Feliu J.X., Vandevuer S., Muller A., Cabrera-Crespo J., Ortmans I., Hoffmann F., Cazorla D., Rinas U., Prevost M., and Villaverde A. Engineering regulable Escherichia coli beta-galactosidases as biosensors for anti-HIV antibody detection in human sera. J. Biol. Chem. 276 (2001) 40087-40095
14. Ferrer-Miralles N., Feliu J.X., and Villaverde A. Molecular mechanisms for antibody-mediated modulation of peptide-displaying enzyme sensors. Biochem. Biophys. Res. Commun. 275 (2000) 360-364
15. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., and Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313 (2003) 387-400
16. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., and Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 (2002) 678-682
17. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
18. Martinez V., Costagliola D., Bonduelle O., N'go N., Schnuriger A., Theodorou I., Clauvel J.P., Sicard D., Agut H., Debre P., Rouzioux C., and Autran B. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J. Infect. Dis. 191 (2005) 2053-2063
19. McCaffrey R.A., Saunders C., Hensel M., and Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78 (2004) 3279-3295
20. Myszka D.G., Sweet R.W., Hensley P., Brigham-Burke M., Kwong P.D., Hendrickson W.A., Wyatt R., Sodroski J., and Doyle ML. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9026-9031
21. Park E.J., Gorny M.K., Zolla-Pazner S., and Quinnan Jr. G.V. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J. Virol. 74 (2000) 4183-4191
22. Park E.J., Vujcic L.K., Anand R., Theodore T.S., and Quinnan Jr. G.V. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol. 72 (1998) 7099-7107
23. Sambrook J., Fritsch E., and Maniatis T. Molecular Cloning, A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
24. Thali M., Charles M., Furman C., Cavacini L., Posner M., Robinson J., and Sodroski J. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 68 (1994) 674-680
25. Ullmann A. One-step purification of hybrid proteins which have beta-galactosidase activity. Gene 29 (1984) 27-31
26. Villaverde A. Allosteric enzymes as biosensors for molecular diagnosis. FEBS Lett. 554 (2003) 169-172
27. Viveros M., Dickey C., Cotropia J.P., Gevorkian G., Larralde C., Broliden K., Levi M., Burgess A., Cao C., Weiner D.B., Agadjanyan M.G., and Ugen KE. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. Virology 270 (2000) 135-145
28. Watkins B.A., Buge S., Aldrich K., Davis A.E., Robinson J., Reitz Jr. M.S., and Robert-Guroff M. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J. Virol. 70 (1996) 8431-8437
29. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw GM. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
30. Zhang P.F., Bouma P., Park E.J., Margolick J.B., Robinson J.E., Zolla-Pazner S., Flora M.N., and Quinnan Jr. G.V. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76 (2002) 644-655